125 related articles for article (PubMed ID: 23601445)
41. Molecular imaging in oncology: Current impact and future directions.
Rowe SP; Pomper MG
CA Cancer J Clin; 2022 Jul; 72(4):333-352. PubMed ID: 34902160
[TBL] [Abstract][Full Text] [Related]
42. CT-based multi-phase Radiomic models for differentiating clear cell renal cell carcinoma.
Chen M; Yin F; Yu Y; Zhang H; Wen G
Cancer Imaging; 2021 Jun; 21(1):42. PubMed ID: 34162442
[TBL] [Abstract][Full Text] [Related]
43. Comparison of Different Machine Models Based on Contrast-Enhanced Computed Tomography Radiomic Features to Differentiate High From Low Grade Clear Cell Renal Cell Carcinomas.
Pei X; Wang P; Ren JL; Yin XP; Ma LY; Wang Y; Ma X; Gao BL
Front Oncol; 2021; 11():659969. PubMed ID: 34123817
[TBL] [Abstract][Full Text] [Related]
44. Differentiation of Clear Cell Renal Cell Carcinoma from other Renal Cell Carcinoma Subtypes and Benign Oncocytoma Using Quantitative MDCT Enhancement Parameters.
Moldovanu CG; Petresc B; Lebovici A; Tamas-Szora A; Suciu M; Crisan N; Medan P; Buruian MM
Medicina (Kaunas); 2020 Oct; 56(11):. PubMed ID: 33126571
[No Abstract] [Full Text] [Related]
45. A CT-Based Radiomics Approach for the Differential Diagnosis of Sarcomatoid and Clear Cell Renal Cell Carcinoma.
Meng X; Shu J; Xia Y; Yang R
Biomed Res Int; 2020; 2020():7103647. PubMed ID: 32775436
[TBL] [Abstract][Full Text] [Related]
46. Discriminating malignant and benign clinical T1 renal masses on computed tomography: A pragmatic radiomics and machine learning approach.
Uhlig J; Biggemann L; Nietert MM; Beißbarth T; Lotz J; Kim HS; Trojan L; Uhlig A
Medicine (Baltimore); 2020 Apr; 99(16):e19725. PubMed ID: 32311963
[TBL] [Abstract][Full Text] [Related]
47. Usefulness of contrast-enhanced ultrasonography for diagnosis of renal cell carcinoma in dialysis patients: Comparison with computed tomography.
Hashimoto M; Ohkuma K; Akita H; Yamada Y; Nakatsuka S; Mizuno R; Oya M; Jinzaki M
Medicine (Baltimore); 2019 Nov; 98(47):e18053. PubMed ID: 31764832
[TBL] [Abstract][Full Text] [Related]
48. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere C; Bassanelli M; Ceribelli A; Rasul S; Li S; Prior JO; Cicone F
Curr Urol Rep; 2019 Oct; 20(11):68. PubMed ID: 31605269
[TBL] [Abstract][Full Text] [Related]
49. Relationship between plasma Atherogenic index and final pathology of Bosniak III-IV renal masses: a retrospective, single-center study.
Karabay E; Karsiyakali N; Duvar S; Tosun C; Aslan AR; Yucebas OE
BMC Urol; 2019 Sep; 19(1):85. PubMed ID: 31519200
[TBL] [Abstract][Full Text] [Related]
50. CT texture analysis in the differentiation of major renal cell carcinoma subtypes and correlation with Fuhrman grade.
Deng Y; Soule E; Samuel A; Shah S; Cui E; Asare-Sawiri M; Sundaram C; Lall C; Sandrasegaran K
Eur Radiol; 2019 Dec; 29(12):6922-6929. PubMed ID: 31127316
[TBL] [Abstract][Full Text] [Related]
51. Core needle biopsy clarify the histology of the small renal masses and may prevent overtreatment.
Azawi NH; Tolouee SA; Madsen M; Berg KD; Dahl C; Fode M
Int Urol Nephrol; 2018 Jul; 50(7):1205-1209. PubMed ID: 29846890
[TBL] [Abstract][Full Text] [Related]
52. Localized chromophobe renal cell carcinoma: preoperative imaging judgment and laparoscopic simple enucleation for treatment.
Ren W; Xue B; Qu J; Liu L; Li C; Zu X
Int Braz J Urol; 2018; 44(5):922-932. PubMed ID: 29757571
[TBL] [Abstract][Full Text] [Related]
53. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
Amin J; Xu B; Badkhshan S; Creighton TT; Abbotoy D; Murekeyisoni C; Attwood KM; Schwaab T; Hendler C; Petroziello M; Roche CL; Kauffman EC
Clin Cancer Res; 2018 Aug; 24(16):3898-3907. PubMed ID: 29752278
[No Abstract] [Full Text] [Related]
54. Correlation of
Rowe SP; Gorin MA; Solnes LB; Ball MW; Choudhary A; Pierorazio PM; Epstein JI; Javadi MS; Allaf ME; Baras AS
EJNMMI Res; 2017 Oct; 7(1):80. PubMed ID: 28971329
[TBL] [Abstract][Full Text] [Related]
55. Role of Contrast Enhancement and Corrected Attenuation Values of Renal Tumors in Predicting Renal Cell Carcinoma (RCC) Subtypes: Protocol for a Triphasic Multi-Slice Computed Tomography (CT) Procedure.
Ertekin E; Amasyalı AS; Erol B; Acikgozoglu S; Kucukdurmaz F; Nayman A; Erol H
Pol J Radiol; 2017; 82():384-391. PubMed ID: 28811845
[TBL] [Abstract][Full Text] [Related]
56. Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?
Rowe SP; Javadi MS; Allaf ME; Gorin MA
EJNMMI Res; 2017 Dec; 7(1):34. PubMed ID: 28405927
[No Abstract] [Full Text] [Related]
57. Qualitative and Quantitative Imaging Evaluation of Renal Cell Carcinoma Subtypes with Grating-based X-ray Phase-contrast CT.
Braunagel M; Birnbacher L; Willner M; Marschner M; De Marco F; Viermetz M; Notohamiprodjo S; Hellbach K; Auweter S; Link V; Woischke C; Reiser MF; Pfeiffer F; Notohamiprodjo M; Herzen J
Sci Rep; 2017 Mar; 7():45400. PubMed ID: 28361951
[TBL] [Abstract][Full Text] [Related]
58. Differentiation of Clear Cell Renal Cell Carcinoma From Other Renal Cortical Tumors by Use of a Quantitative Multiparametric MRI Approach.
Hötker AM; Mazaheri Y; Wibmer A; Karlo CA; Zheng J; Moskowitz CS; Tickoo SK; Russo P; Hricak H; Akin O
AJR Am J Roentgenol; 2017 Mar; 208(3):W85-W91. PubMed ID: 28095036
[TBL] [Abstract][Full Text] [Related]
59. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X
Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764
[TBL] [Abstract][Full Text] [Related]
60. Computed Tomography Appearance of Renal Hybrid Oncocytic/Chromophobe Tumors.
Bhatnagar A; Rowe SP; Gorin MA; Pomper MG; Fishman EK; Allaf ME
J Comput Assist Tomogr; 2016; 40(4):513-6. PubMed ID: 27096398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
